Selected article for: "immune response and ligase activity"

Author: Wilson, Van G.
Title: Sumoylation at the Host-Pathogen Interface
  • Document date: 2012_4_5
  • ID: 1awau7hm_26
    Snippet: In contrast to the HPV 16E6 protein, the Ebola VP35 protein stimulates the ligase activity of its target, PIAS1. PIAS1 is an endogenous SUMO ligase for IRF7. Sumoylation of IRF7 decreases its transcriptional activity on the interferon β promoter and may be part of a normal feedback process to attenuate the interferon response and limit inflammation. In co-immunoprecipitations VP35 was found complexed to both PIAS1 and IRF7, and VP35 expression l.....
    Document: In contrast to the HPV 16E6 protein, the Ebola VP35 protein stimulates the ligase activity of its target, PIAS1. PIAS1 is an endogenous SUMO ligase for IRF7. Sumoylation of IRF7 decreases its transcriptional activity on the interferon β promoter and may be part of a normal feedback process to attenuate the interferon response and limit inflammation. In co-immunoprecipitations VP35 was found complexed to both PIAS1 and IRF7, and VP35 expression led to enhanced sumoylation of IRF7 that reduced its transcriptional activity. When co-expressed with a PIAS1 inactive mutant VP35 was unable to enhance sumoylation of IRF7, indicating that the VP35 effect on IRF7 is mediated through PIAS1 alone. Normally IRF7 is sumoylated at lysine 406, but VP35 induced sumoylation at multiple lysines, even in a lysine 406 mutant, suggesting that VP35 is causing promiscuous sumoylation of this target to ensure its transcriptional repression. Similar effects were seen with IRF3. Consequently, it appears that Ebola is using VP35 to down regulate the innate immune response by hypersumoylating two transcription factors involved in interferon induction to reduce their transactivation capacity and decrease interferon production.

    Search related documents:
    Co phrase search for related documents
    • co immunoprecipitation and innate immune response: 1, 2, 3, 4, 5
    • co immunoprecipitation and interferon production: 1, 2, 3, 4, 5
    • co immunoprecipitation and interferon response: 1, 2
    • co immunoprecipitation and ligase activity: 1, 2
    • β promoter and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • β promoter and innate immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • β promoter and interferon β promoter: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • β promoter and interferon induction: 1, 2, 3, 4
    • β promoter and interferon production: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • β promoter and interferon response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • immune response and innate immune response regulate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • immune response and interferon β promoter: 1, 2, 3
    • immune response and interferon induction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • immune response and interferon production: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • immune response and interferon production decrease: 1
    • immune response and interferon response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • immune response and ligase activity: 1, 2, 3, 4
    • immune response and limit interferon response: 1
    • immune response and multiple lysine: 1